EMulate Therapeutics Statistics
Total Valuation
EMTX has a market cap or net worth of $69.31 million. The enterprise value is $79.51 million.
| Market Cap | 69.31M |
| Enterprise Value | 79.51M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
EMTX has 13.86 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 13.86M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 271.81 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 311.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | $36,429 |
| Profits Per Employee | -$4.00M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EMTX had revenue of $255,000 and -$28.02 million in losses. Loss per share was -$2.02.
| Revenue | 255,000 |
| Gross Profit | 255,000 |
| Operating Income | -15.97M |
| Pretax Income | -28.02M |
| Net Income | -28.02M |
| EBITDA | -23.90M |
| EBIT | -24.66M |
| Loss Per Share | -$2.02 |
Balance Sheet
The company has $10,000 in cash and $10.21 million in debt, giving a net cash position of -$10.20 million or -$0.74 per share.
| Cash & Cash Equivalents | 10,000 |
| Total Debt | 10.21M |
| Net Cash | -10.20M |
| Net Cash Per Share | -$0.74 |
| Equity (Book Value) | -23.91M |
| Book Value Per Share | -1.72 |
| Working Capital | -19.75M |
Cash Flow
In the last 12 months, operating cash flow was -$3.87 million and capital expenditures -$7,000, giving a free cash flow of -$3.88 million.
| Operating Cash Flow | -3.87M |
| Capital Expenditures | -7,000 |
| Free Cash Flow | -3.88M |
| FCF Per Share | -$0.28 |
Margins
Gross margin is 100.00%, with operating and profit margins of -6,264.31% and -10,989.41%.
| Gross Margin | 100.00% |
| Operating Margin | -6,264.31% |
| Pretax Margin | -10,989.41% |
| Profit Margin | -10,989.41% |
| EBITDA Margin | -9,370.59% |
| EBIT Margin | -9,670.59% |
| FCF Margin | -1,520.39% |
Dividends & Yields
EMTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -40.43% |
| FCF Yield | -5.59% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |